eFFECTOR Therapeutics, Inc. (EFTR)
OTCMKTS: EFTR · Delayed Price · USD
0.0460
-0.0005 (-1.08%)
Jul 26, 2024, 3:52 PM EDT - Market closed
eFFECTOR Therapeutics Employees
eFFECTOR Therapeutics had 14 employees as of December 31, 2023. The number of employees decreased by 1 or -6.67% compared to the previous year.
Employees
14
Change (1Y)
-1
Growth (1Y)
-6.67%
Revenue / Employee
$11,571
Profits / Employee
-$2,473,571
Market Cap
216.40K
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 14 | -1 | -6.67% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
EFTR News
- 4 weeks ago - eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq - GlobeNewsWire
- 2 months ago - eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewsWire
- 2 months ago - eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - eFFECTOR Therapeutics to Participate in Upcoming Investor Conference - GlobeNewsWire
- 4 months ago - eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer - GlobeNewsWire
- 4 months ago - eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 6 months ago - eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire